To our knowledge, this is the first study to systematically generate and functionally assess the role of osimertinib and savolitinib combination in osimertinib-resistant EGFR-mutant NSCLC PDX models with heterogenous MET pathway activation. Here, MET is linked to non-small cell lung carcinoma.